223 results about "Ovarian function" patented technology

The invention discloses a traditional Chinese medicine composition, a preparation method thereof and an application of the traditional Chinese medicine composition in preparation of a medicine for preventing and treating ovarian reserve hypofunction, and belongs to the technical field of traditional Chinese medicines. The composition is prepared from the following raw materials in parts by weight: 10 to 15 parts of radix paeoniae alba, 6 to 10 parts of radix bupleuri, 10 to 15 parts of radix rehmanniae preparata, 15 to 30 parts of stir-fried rhizoma dioscoreae, 12 to 20 parts of semen cuscutae, 10 to 12 parts of radix angelicae sinensis, 10 to 15 parts of poria cocos, 12 to 25 parts of fructus ligustri lucidi, 10 to 15 parts of radix salviae miltiorrhizae, 10 to 15 parts of fructus corni and 10 to 15 parts of radix morindae officinalis. The traditional Chinese medicine composition can obviously reduce the level of follicle-stimulating hormone (FSH) of cis-platinum model mice, increase estradiol (E2), increase the number of follicles at all levels, especially the number of primordial follicles, and reduce the number of atresia follicles; the ovarian function of naturally aged mice can be improved, FSH (follicle stimulating hormone) is reduced, anti-mullerian hormone (AMH) and E2 are increased, and the quantity of follicles at all levels, especially the quantity of corpus luteum, primordial follicles and anterior sinus follicles, is increased; therefore, the composition disclosed by the invention has an obvious protection effect on the hypoovarian reserve function.

The invention discloses an ovarian protection composition containing ergothioneine and a preparation method of the ovarian protection composition, and relates to the technical field of ovarian protection compositions. The ovary protection composition containing the ergothioneine is prepared from the following components in parts by mass: 0.1 to 0.5 part of the ergothioneine, 0.05 to 1 part of S-equol, 1 to 5 parts of reducing coenzyme Q10, 1 to 3 parts of vitamin E, 10 to 20 parts of chitosan oligosaccharide, 30 to 50 parts of microcrystalline cellulose, 3 to 8 parts of hydroxypropyl methyl cellulose, 0.5 to 2 parts of silicon dioxide and 0.5 to 2 parts of a stabilizer. By adopting the stabilizer, photooxidation and hydrolysis of sensitive components are inhibited through molecular action, and the long-term stability of the composition in a humid and hot environment is remarkably improved in combination with the physical barrier action of silicon dioxide. Through the antioxidant synergistic effect of the ergothioneine and the vitamin E, the hormone regulation effect of the S-equol and the energy metabolism improvement effect of the coenzyme Q10, a multi-layer ovarian function protection system is constructed, and the health state of ovaries is improved. Through a special process, the tablet can be rapidly disintegrated and slowly released in an intestinal targeted manner, burst release of active ingredients is avoided, and the absorption efficiency is improved.

The invention belongs to the technical field of cytotoxicity intervention, and particularly relates to application of an inhibitor JSH-23 in preparation of a medicine for preventing and / or treating ovarian toxicity caused by environmental toxin combined exposure. Aiming at the condition that MC-LR and NaNON combined exposure can activate NF-kappa B to induce KK-1 cell nitrification stress and cause mouse ovarian dysfunction, JSH-23 is selected as an intervention agent, and it is found that after KK-1 cells are pretreated by JSH-23, NF-kappa B nuclear translocation induced by the KK-1 cells due to MC-LR and NaNON combined exposure is remarkably inhibited, iNOS protein rising induced by toxin combined exposure is remarkably reduced, and NF-kappa B nuclear translocation induced by the KK-1 cells due to NF-kappa B combined exposure is remarkably inhibited. The increase of the levels of ONOO and 3-NT of nitration stress markers is effectively relieved, which indicates that JSH-23 can participate in the nitration stress of KK-1 cells caused by combined exposure of MC-LR and NaNO2 by inhibiting NF-kappa B activation, and a foundation is laid for screening antidotes after exposure of environmental toxins.

The invention discloses a traditional Chinese medicine composition for repairing and / or activating residual ovarian functions of an aging ovary, and a preparation method and application thereof, and relates to the technical field of biology. The traditional Chinese medicine composition is prepared from the following components: radix astragali, radix angelicae sinensis, radix ophiopogonis, radix polygonati officinalis, semen cuscutae, radix morindae officinalis, fructus rubi, rhizoma dioscoreae and folium mori. The invention further provides application of the traditional Chinese medicine composition in repairing and / or activating the residual ovarian function of the senescent ovary and improving the quality of the senescent oocyte, the traditional Chinese medicine composition can increase the volume and weight of the senescent ovary, increase the number of follicles of all levels in the senescent ovary, reduce apoptosis of granular cells in the ovary and improve the survival rate of the senescent ovary. The abnormal rate of oocytes, oxidative stress of the oocytes and DNA damage are reduced, development and maturation of residual follicles are promoted and maintained, and the traditional Chinese medicine composition has a wide application prospect.

The invention provides a traditional Chinese medicine composition for treating ovarian reserve function decline. The traditional Chinese medicine composition is prepared from the following medicines in parts by mass: 9-30 parts of radix astragali preparata, 6-20 parts of roasted rhizoma atractylodis macrocephalae, 10-15 parts of poria cocos, 2-10 parts of radix glycyrrhizae preparata, 6-20 parts of semen cuscutae, 9-20 parts of radix dipsaci (dipsacus root), 6-12 parts of herba lycopi and 6-15 parts of lily. Experimental results show that the traditional Chinese medicine composition is suitable for improving the ovarian function of a patient suffering from spleen-kidney deficiency type ovarian reserve function decline.

The invention discloses application of amniotic mesenchymal stem cells in preparation of a medicine for improving and / or treating premature ovarian failure. The invention finds that the amniotic mesenchymal stem cells can significantly improve the granular cell proliferation ability and hormone secretion ability, and the premature ovarian failure animal model proves that the amniotic mesenchymal stem cells have leading treatment effects in the aspects of restoring the ovarian functions (hormone secretion, ovary volume and follicle number of each level) of POF mice and improving fertility again. And a foundation is laid for optimizing a treatment strategy of premature ovarian failure and promoting clinical application of mesenchymal stem cell treatment.

The present invention discloses the application of MY-1B in the preparation of drugs for improving ovarian senescence, belonging to the technical field of biomedicine, aiming to solve the problem of how to effectively delay ovarian senescence and improve ovarian function. Experiments have proved that during ovarian senescence, the mRNA m<supgt;5< / supgt;C modification level and the expression level of methyltransferase in ovarian granulosa cells increase. Supplementation with MY-1B can improve the condition caused by mRNA m Nsun2 expression.

The invention discloses application of an ACSL4 inhibitor in preparation of a medicine for improving quality reduction of an elderly ovum, and belongs to the technical field of biological medicines. The invention provides an application of targeting long-chain fatty acid acyl-coenzyme A synthetase 4 (ACSL4) in intervention of low oocyte quality and related fertility decline caused by aging. The ACSL4 inhibitor can be used for preparing drugs for improving ovarian functions and improving oocyte quality. In-vivo and in-vitro experiments prove that by inhibiting the ACSL4, the aging process of the elderly ovary can be effectively relieved, the expression of aging-related proteins p16 and p21 can be reduced, the mitochondrial function of the oocyte can be improved, and spindle assembly abnormality and chromosome arrangement defects can be rescued, so that the maturation rate and the development potential of the oocyte can be remarkably improved.

The invention provides application of a traditional Chinese medicine composition in preparation of a medicine for preventing and / or treating ovarian dysfunction, and belongs to the technical field of biological medicine. The traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 8-10 parts of American ginseng, 2-4 parts of pseudo-ginseng, 55-65 parts of kudzuvine root, 42-48 parts of coptis chinensis, 42-48 parts of scutellaria baicalensis, 14-16 parts of stiff silkworm, 14-16 parts of rhizoma zingiberis, 42-48 parts of bitter gourd and 55-65 parts of rhizoma anemarrhenae. The traditional Chinese medicine composition has the effects of increasing the number of follicles and corpus luteum, restoring the duration of an estrus cycle and restoring the levels of serum hormones and sex hormone receptors. The traditional Chinese medicine composition provided by the invention provides a new means for preventing and treating ovarian dysfunction.

The invention belongs to the field of animal model construction, and particularly relates to application of an NFATC2IP gene knockout mouse model. Experiments prove that after the NFATC2IP gene is knocked out, the mouse has the characteristic changes of ovarian weight reduction, volume reduction, estrus cycle disorder, fertility reduction, AMH reduction, FSH increase and the like. It is indicated that the NFATC2IP gene is a key factor for maintaining ovarian reserve and endocrine balance, and an NFATC2IP gene knockout mouse can be used for revealing the occurrence mechanism of ovarian dysfunction and can also be used for screening of novel ovarian protection drugs, research of a hormone regulation mechanism and discovery and verification of biomarkers.

The application discloses application of NCOA7 circular RNA nanoliposome in preparation of a drug for treating premature ovarian failure or ovarian reserve function decline, and belongs to the technical field of biological medicine.The present application proves that nuclear receptor coactivator 7 (NCOA7) can relieve ovarian aging and significantly improve the ovarian function and fertility of DOR patients.The present application finds that NCOA7 circular RNA nanoliposome treatment can significantly improve the NCOA7 protein expression level of DOR female ovarian granulosa cells, improve the aging phenotype and growth rate of the DOR female ovarian granulosa cells, and has no significant influence on the biological characteristics of the ovarian granulosa cells, thereby providing a new scheme for rescuing the ovarian function and improving the fertility of DOR women.

The invention provides a novel application of a raspberry extract. It is found through tests that any one of isoquercitrin, ellagic acid, vanillic acid, oleanolic acid, kaempferol-3-O-rutinoside, kaempferol-3-O-sophoroside, tiliroside, tormentic acid and raspberry extract can remarkably improve the activity of the human ovarian granular cells or remarkably improve the oxidative stress level, and the activity of the human ovarian granular cells can be remarkably improved. According to the present invention, the ovarian function can be effectively protected by the eight components, the ovarian function can be effectively protected by the eight components, or the mitochondrial membrane potential level can be significantly regulated and controlled, or the estrogen level in the microenvironment can be effectively maintained, such that the ovarian function can be effectively protected by the eight components, and the raspberry extract containing the eight components. The invention provides a new choice for ovarian function protection products, and also provides a new application for the substances.

The invention discloses application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period, belongs to the technical field of feed additives, and particularly relates to application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period. It is found that paeonol can significantly reduce the activity of glutamic-pyruvic transaminase in the liver, significantly reduce the content of cholesterol and the content of triglyceride in serum, significantly reduce hepatic cell fatty degeneration and lipid droplet aggregation in a hepatic tissue pathological section, relieve liver injury and lipid metabolism disorder, and significantly improve the liver function. The paeonol can effectively improve the fatty liver hemorrhagic syndrome of the laying hens in the later egg laying period, and the paeonol can recover the storage capacity of ovary by improving the survival rate of follicles, improve the egg laying performance of the laying hens and improve the egg laying rate.

The present application relates to the field of biological medicine and modernization of traditional Chinese medicine, and particularly relates to a therapeutic target, an inhibitor and a traditional Chinese medicine composition for treating ovarian hypofunction caused by oxidative stress and application thereof. The present application first determines SRC tyrosine kinase as a key drug target for preventing and treating the disease. The application of the SRC tyrosine kinase inhibitor (such as secaitinib) in preparing related drugs is provided, which can alleviate the damage of ovarian granulosa cells by inhibiting the SRC activity, down-regulating the expression of antioxidant enzyme related genes and reducing the level of active oxygen. Meanwhile, the present application provides a traditional Chinese medicine composition composed of mulberry, kudzu root, tuckahoe and medlar. The composition can improve the hormone level, enhance the antioxidant capacity, improve the ovarian function and fertility by inhibiting the SRC tyrosine kinase activity and the SRC-RAF1-MEK-ERK signal pathway. The present application provides a new solution for the targeted treatment of ovarian hypofunction and the modernization of traditional Chinese medicine.

The invention relates to application of a gene inhibitor in preparation of a medicine for treating ovulation dysfunction, and belongs to the field of biomedicine.The FST content in serum of a healthy person and an OD patient is compared, it is found that the FST content in serum of the OD patient is far higher than that in serum of the healthy person, and then it is obtained that the FST content can be used as the basis for judging that the patient suffers from ovulation dysfunction. Therefore, early intervention and treatment can be carried out on patients. According to the invention, the FST high-expression monkey model is successfully constructed, and the pathogenic effect of FST high expression on the OD pathogenesis process is obtained through research of the FST high-expression monkey model; the invention further designs specific shRNA (short hairpin ribonucleic acid) to successfully inhibit the expression of FST, and after the expression of FST is inhibited, the ovarian structure of the test monkey tends to be healthy, the follicular development is normal, and the ovulation regularity is recovered, and the results show that the inhibition of the FST gene has a remarkable promotion effect on the ovarian function.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to Kunxinning and a preparation method and application thereof. The effective components of the Kunxingning disclosed by the invention are artemisinin and artemisinin. Animal experiments prove that kunxingning can improve the early-onset ovarian insufficiency toxicity state of SD rats caused by tripterygium glycosides, reduce ovarian granular cell apoptosis, improve the ovarian pathological state, promote follicular development, restore the serum sex hormone level to be normal to a certain extent, improve the state of proportion imbalance of Th17 / Treg immune cells, and improve the early-onset ovarian insufficiency toxicity of the SD rats. And the mood cycle of the rats is recovered to a certain extent. Meanwhile, the physiological activity of the tripterygium glycosides composition obtained by compounding the kunxingning and the TG is equivalent to that of the TG.

The present invention relates to the technical field of pharmaceuticals. Particularly, disclosed is use of finerenone in the preparation of a drug for treating and / or preventing ovarian dysfunction diseases. Provided is a novel, safe, and effective composition for treating ovarian dysfunction diseases. Finerenone, as a main component in the preparation of the drug for treating and / or preventing the ovarian dysfunction diseases, can be applied orally, which reduces the pain and injury to patients and is more convenient, thereby providing a safe and effective new choice for the use in the preparation of the drug for treating and / or preventing the ovarian dysfunction diseases.

The invention discloses application of spermidine in preparation of a preparation for improving fertility of female mammals, and belongs to the technical field of reproductive biology. According to the invention, spermidine with different concentrations is introduced into mice, and the effect of spermidine on ovarian hormone secretion, ovarian reserve level and follicle number of female mammals is determined in a diet intake manner, so that the fertility of female animals is improved; it is found that spermidine can effectively improve the ovarian function, increase the secretion level of E2, P4, LH and AMH hormones closely related to the ovarian function, reduce the number of atresia follicles of the ovarian and increase the litter birth number of female mice by 1-2, and the spermidine has good animal breeding and livestock raising application prospects.

The invention discloses an application of a small molecular compound and an analogue thereof in treating ovarian aging diseases. It is found for the first time that the exogenous supplementary adenosine or the analogues thereof can effectively recover or improve the ovarian function and can prevent and inhibit ovarian fibrosis, and therefore the exogenous supplementary adenosine or the analogues thereof can be used as potential drugs for recovering the female fertility.

The application discloses a doxorubicin scavenger for protecting ovarian fertility and a preparation method thereof, comprising a DNA complex wrapped by a red blood cell membrane, wherein the red blood cell membrane is surface-modified by an anti-Mullerian duct antibody alphaAMH; the doxorubicin scavenger is specifically combined with AMH which is highly expressed in ovarian tissues through alphaAMH, is enriched in the ovarian part in a targeted manner, adsorbs doxorubicin through a DNA fragment in the DNA complex, reduces toxic damage of doxorubicin to ovarian cells, and further protects ovarian fertility. The doxorubicin scavenger can adsorb injected doxorubicin Dox, reduce side effects of doxorubicin Dox on ovarian granulosa cells, and further protect ovarian function and fertility.

The invention discloses a synergistic anti-oxidation urolithin A composition and application thereof in improving the ovarian function direction, and relates to the technical field of biological medicine, and the active ingredients of the composition comprise 10-100 parts of urolithin A and 6-40 parts of coenzyme Q10. According to the composition disclosed by the invention, the used raw materials are food-grade raw materials such as urolithin A and coenzyme Q10, and the urolithin A and the coenzyme Q10 are matched within a certain range, so that a good synergistic interaction effect can be achieved, and the composition has a good antioxidant effect; meanwhile, the composition also has the effects of effectively improving the ovarian reserve function, regulating the hormone level, improving menstruation, skin, emotion, sleep and the like at a low dosage level, and is effective and safe.

The invention relates to an effect of an REV-ERBalpha agonist SR9009 in the aspect of delaying ovarian senescence, and aims at the problem of fertility decline caused by cliff-type decline of ovarian functions of women over 35 years old, the SR9009 is applied to activate an REV-ERBalpha circadian rhythm signal channel in ovarian tissues, inhibit excessive autophagy of granular cells and maintain a primordial follicle dormancy state, so that the agonist SR9009 can be used for delaying ovarian senescence. Therefore, the original follicle depletion speed is delayed, follicle storage is maintained, and the ovary reproductive function cycle is prolonged. The effect is verified by a mammal model: REV-ERBalpha protein expression in an ovary of an aging individual is reduced, rhythmicity expression is disordered, autophagy of granulosa cells can be effectively inhibited in the ovary of the aging individual intervened by the SR9009, and the number of residual primordial follicles and the number of total follicles are obviously greater than those of an untreated control group. The invention provides an innovative treatment strategy of targeted rhythm regulation and control for clinical intervention of ovarian aging.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for improving ovarian function damage and degeneration and a preparation method thereof. The invention discloses the GnRH agonist effect of dihydromyricetin DMY for the first time, and the affinity of dihydromyricetin DMY to a GnRH receptor and the GnRH agonist effect of dihydromyricetin DMY are verified through in-vitro experiments. Model animal experiments further prove that the dihydromyricetin DMY has a protective effect on ovarian function impairment caused by chemotherapy. Experiments prove that the dihydromyricetin DMY is given while the cyclophosphamide (CTX) is used for chemotherapy, so that the damage of the dihydromyricetin DMY to the ovarian function during chemotherapy can be reduced, and a protection effect is also achieved on the recovery of the ovarian function after drug withdrawal. The protection effect is reflected on the endocrine function and the reserve function of the ovary, and the preserved ovary reserve function can achieve the pregnancy result after chemotherapy is finished, which indicates that the dihydromyricetin DMY also plays the protection effect on the fertility function of the ovary.

One aspect of the invention provides a method of ovarian protection by administering to a female subject a composition comprising Mullerian inhibiting substance (MIS). Ovarian protection can be an induced arrest of folliculogenesis to preserve fertility. In some embodiments, ovarian protection is oncoprotection, the protection of the ovarian function during a cytotoxic treatment, e.g., chemotherapy. Another aspect of the invention relates to a method of treating PCOS, the method comprising administering to a female subject a composition comprising recombinant MIS protein.

The invention discloses an oral drug delivery system with a double-emulsion structure and application of the oral drug delivery system in preparation of drugs for treating premature ovarian insufficiency, and belongs to the technical field of biological medicines. The oral drug delivery system comprises droplet particles formed by wrapping an MSCs conditioned culture medium with an oil-phase solvent, and exosomes uniformly distributed on the outer surfaces of the droplet particles, so that a double-emulsion structure is formed. Water-soluble MSC-CM is wrapped by a water-in-oil-in-water method to form a double-emulsion structure, so that water-soluble protein enters a human body to be absorbed in an oral manner. The MSC-CM composite has good structural stability and viscoelasticity, the particle size range is about 10-50 microns, contact with intestinal epithelial cells can be increased, meanwhile, the skeleton of the intestinal epithelial cells can be changed, expression of tight junction protein of the intestinal epithelial cells can be lowered, tight junction barriers of the intestinal epithelial cells can be opened, and therefore the bioavailability of MSC-CM is improved, and the MSC-CM composite has a good application prospect. The effect of treating the POI is achieved.

The invention provides a premature ovarian insufficiency (POI) animal model and a construction method thereof, and particularly, the method utilizes chronic unpredictable pressure stress to construct different pathological stage models of mouse POI, and comprises the following steps: screening experimental animals with normal ovarian functions, adaptively feeding, applying various pressure stresses to the experimental animals, and obtaining the POI animal model. The POI model has a compensatory period, and is more in line with the clinical pathological process of patients suffering from premature ovarian insufficiency caused by common pressure in modern society.

The invention discloses a traditional Chinese medicine composition for treating hypoovarian reserve function. The traditional Chinese medicine composition comprises the following raw material medicines: 10-30 parts of vinegar tortoise shell, 10-15 parts of prepared rehmannia root, 6-20 parts of salt-processed semen cuscutae, 9-15 parts of wine-processed rhizoma polygonati, 10-30 parts of radix puerariae, 9-15 parts of polygonum cuspidatum, 6-20 parts of acanthopanax, 5-15 parts of salvia miltiorrhiza, 6-10 parts of roasted herba epimedii and 3-10 parts of pericarpium citri reticulatae. The invention further discloses application of the traditional Chinese medicine composition in preparation of a medicine for treating ovarian reserve hypofunction. The traditional Chinese medicine composition has the effects of improving the ovarian function and the sex hormone level, increasing the AFC quantity, adjusting the ovarian blood flow state, improving the menstrual condition, the traditional Chinese medicine syndrome and the anxiety level of a patient and improving the clinical pregnancy rate, and is safe and reliable.

The present invention relates to the technical field of medical detection. Disclosed is a use of an ERAP2 detection reagent in the preparation of a product for predicting the prognosis of POI. Also disclosed in the present invention is a use of ERAP2 as a biomarker in the preparation of a product for predicting the prognosis of POI. The prognosis of POI is intermittent recovery of ovarian function and / or a pregnancy outcome. In the present invention, it has been found by means of experimental studies that a serum ERAP2 level has a significant association with the prognosis of a POI patient, is an independent influencing factor, and has relatively high specificity and sensitivity. Therefore, ERAP2 can serve as a biomarker for predicting the prognosis of POI. The present invention provides a theoretical basis and clinical practice guidance for the prognosis of POI, and has important application value.

Provided are a biological material for restoring ovarian functions, a preparation method therefor and the use thereof, relating to the technical field of biological materials. A large number of experiments verify that: it is found that a specific biological protein component for reversing ovarian functions in extracellular vesicles is the growth differentiation factor 9 (GDF-9), and the mechanism of action thereof for restoring the ovary is determined, and therefore extracellular vesicles (GOEs) that overexpress GDF-9 serve as an active substance, and by means of extraction and purification of said component, the purpose of targeted therapy is achieved.

Provided is use of thyroxine and a thyroxine receptor inhibitor in preparing drugs for regulating primordial follicle activation, belonging to the technical field of biology. It has been discovered that the thyroxine can promote primordial follicle activation, and the thyroxine receptor inhibitor inhibits primordial follicle activation, so that they can be used as drugs for regulating primordial follicle activation in patients with premature ovarian insufficiency.